German report on benefit assessment a miss for drug industry; HTA grants strongest endorsement yet
This article was originally published in SRA
Executive Summary
A government report on the tough pricing and reimbursement system that Germany introduced under the AMNOG healthcare reform act has failed to address key problems with the system, according to Matthias Heck, Brussels representative for the BPI, a German pharmaceutical industry association. Separately, a drug has recently won the strongest endorsement yet from German health technology appraisal institute IQWiG for a product passing through the AMNOG system1-3.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.